These drugs have caused a revolution in the diabetes and weight loss arenas not only due to their success, but also because of their cost
Early study results may support further research into how GLP-1 analogs might treat RA
Animal experiments were approved by the Wako Animal Experiment Committee in RIKEN (approval number: W2021-2-020(1))
Combined use of both compounds is entirely unstudied in humans and carries unpredictable metabolic and cardiovascular risks
Obesity and overweight, which are common in patients with DM2, are a factors that favor the development/progression of CKD through both direct and indirect effects.69 Although the precise mechanisms the association between obesity and CKD are not totally defined it has been proposed that hypertension, glomerular hyperfiltration, hyperglycemia, lipid toxicity, inflammation or the role of adipose tissue and its adipokines are involved.70 Weight reduction by bariatric surgery, pharmacological treatment or dietary measures are associated with a nephroprotective effect,7173 so that weight reduction is a fundamental objective in the nephroprotection of patients with DKD
